Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 17/20 | 0.64 |
| ▸ | AGXT | P21549 | 11/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17289457 | 0.97 | IDO1 (0.65) | IDO1AGXTCYP3A4 | |
| SCHEMBL438248 | 0.88 | IDO1 (0.78) | IDO1AGXTCYP3A4 | |
| SCHEMBL234606 | 0.80 | ALDH1A1 (0.55) | CYP3A4 | |
| SCHEMBL6340074 | 0.78 | IDO1 (1.00) | IDO1AGXTCYP3A4 | |
| SCHEMBL5912621 | 0.78 | IDO1 (0.64) | IDO1AGXTCYP3A4 | |
| SCHEMBL18818093 | 0.76 | APP (0.52) | IDO1CYP3A4 | |
| SCHEMBL4302217 | 0.76 | TSHR (0.50) | CYP3A4 | |
| SCHEMBL13372043 | 0.76 | IDO1 (0.61) | IDO1AGXTCYP3A4 | |
| SCHEMBL3154601 | 0.76 | AGXT (1.00) | IDO1AGXTCYP3A4 | |
| SCHEMBL513260 | 0.76 | TDP1 (0.50) | IDO1AGXTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118434765-A | BCMA monoclonal antibodies and antibody-drug conjugates | 杭州多禧生物科技有限公司 | 2024-08-02 | — | — | CN | claimed |
| CN-112272669-A | Cross-linked pyrrolobenzodiazepine dimer (PBD) derivatives and conjugates thereof | 杭州多禧生物科技有限公司 | 2021-01-26 | — | — | CN | claimed |
| CN-110621673-A | Double-stranded linked cytotoxic drug conjugates | 杭州多禧生物科技有限公司 | 2019-12-27 | — | — | CN | claimed |
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-115821314-A | Method for preparing p-nitrobenzol by electro-reduction hydrogenation of Pd/Cu-CF catalyst | 北京林业大学 | 2023-03-21 | — | — | CN | disclosed |
| WO-2021020585-A1 | HETEROCYCLIC COMPOUND | ファイメクス株式会社 | 2021-02-04 | — | — | WO | disclosed |
| CN-112272669-A | Cross-linked pyrrolobenzodiazepine dimer (PBD) derivatives and conjugates thereof | 杭州多禧生物科技有限公司 | 2021-01-26 | — | — | CN | disclosed |
| CN-110621673-A | Double-stranded linked cytotoxic drug conjugates | 杭州多禧生物科技有限公司 | 2019-12-27 | — | — | CN | disclosed |
| US-20150343413-A1 | METHOD FOR DIRECT PHOTOPATTERNING OF MOLECULES ON SURFACES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-12-03 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885AGXT 365/4885CYP3A4 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.